Background::The global pandemic coronavirus disease 2019 (COVID-19) has become a major public health problem and presents an unprecedented challenge. However, no specific drugs were currently proven. This study aimed to evaluate the comparative efficacy and safety of pharmacological interventions in patients with COVID-19.Methods::Medline, Embase, the Cochrane Library, and clinicaltrials.gov were searched for randomized controlled trials (RCTs) in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)/SARS-CoV. Random-effects network meta-analysis within the Bayesian framework was performed, followed by the Grading of Recommendations Assessment, Development, and Evaluation system assessing the quality of evidence. The primary outcome of interest includes mortality, cure, viral negative conversion, and overall adverse events (OAEs). Odds ratio (OR) with 95

作者：Wu Shan-Shan；Zhou Qing-Xin；Zeng Xue-Yang；Zhang Jing-Xue；Yang Zhi-Rong；Yang Qing-Qing；Zhang Zi-Lu；Chen Ya-Hong；Sun Feng；Zhan Si-Yan

来源：中华医学杂志英文版 2021 年 134卷 16期